DuPaul G J, Barkley R A, McMurray M B
Department of Counseling Psychology, School Psychology, and Special Education, Lehigh University, Bethlehem, PA 18015.
J Am Acad Child Adolesc Psychiatry. 1994 Jul-Aug;33(6):894-903. doi: 10.1097/00004583-199407000-00016.
The purpose of this study was to examine differences in methylphenidate (MPH) response between groups of children with attention-deficit hyperactivity disorder (ADHD) who exhibited varying degrees of internalizing symptoms.
A sample of 40 children with ADHD was subdivided into three groups based on the severity of comorbid internalizing symptoms. Differential effects of three doses of MPH (5 mg, 10 mg, 15 mg) were evaluated in a double-blind, placebo-controlled fashion using multiple outcome measures across home, school, and clinic settings.
Children with ADHD and comorbid internalizing symptoms were significantly less likely to respond positively to MPH than were their noninternalizing counterparts according to teacher ratings and behavioral observations during a clinic-based academic task.
Children who exhibit comorbid symptoms of ADHD and internalizing disorder are less likely to respond to MPH in classroom settings and on academic tasks. A significant minority of children with comorbid conditions may be at a higher risk for an adverse medication response relative to patients with ADHD who are not exhibiting internalizing symptoms. Further research is necessary to delineate the characteristics of possible adverse responders.
本研究旨在探讨患有注意力缺陷多动障碍(ADHD)且内化症状程度不同的儿童组之间在哌甲酯(MPH)反应上的差异。
将40名患有ADHD的儿童样本根据共病内化症状的严重程度分为三组。采用双盲、安慰剂对照的方式,使用家庭、学校和诊所环境中的多种结果测量方法,评估三种剂量的MPH(5毫克、10毫克、15毫克)的不同效果。
根据基于诊所的学术任务期间的教师评分和行为观察,患有ADHD和共病内化症状的儿童对MPH产生积极反应的可能性明显低于无内化症状的儿童。
表现出ADHD和内化障碍共病症状的儿童在课堂环境和学术任务中对MPH产生反应的可能性较小。相对于未表现出内化症状的ADHD患者,相当一部分患有共病的儿童可能有更高的药物不良反应风险。需要进一步研究来描述可能的不良反应者的特征。